Investment Thesis
BIO KEY INTERNATIONAL is in severe financial distress with negative operating cash flow of -$2.8M, deteriorating profitability (net margin of -59.1%), and declining revenue (-10.6% YoY). The company is cash-consuming with operating losses exceeding $2.6M despite maintaining a healthy 77.3% gross margin, indicating fundamental business model challenges beyond cost structure.
Strengths
- Strong gross margin of 77.3% suggests pricing power and product efficiency at the direct cost level
- Zero long-term debt eliminates refinancing and solvency risk in near term
- Adequate liquidity with current ratio of 1.26x and $2.0M cash provides runway for operations
Risks
- Negative operating cash flow of -$2.8M indicates the business is not self-sustaining and burning cash
- Revenue declining 10.6% YoY combined with widening operating losses suggests loss of market competitiveness
- Large gap between high gross margin and negative operating margin indicates severe operational inefficiency and high fixed costs relative to revenue base
- Negative ROE of -47.5% and ROA of -28.4% demonstrate poor capital utilization and shareholder value destruction
Key Metrics to Watch
- Operating cash flow trend and path to positive cash generation
- Revenue stabilization and return to growth trajectory
- Operating expense reduction relative to revenue base to achieve operating profitability
- Cash runway and adequacy of $2.0M in light of $2.8M annual cash burn rate
Financial Metrics
Revenue
4.9M
Net Income
-2.9M
EPS (Diluted)
$-0.01
Free Cash Flow
-2.8M
Total Assets
10.1M
Cash
2.0M
Profitability Ratios
Gross Margin
77.3%
Operating Margin
-53.9%
Net Margin
-59.1%
ROE
-47.5%
ROA
-28.4%
FCF Margin
-58.6%
Balance Sheet & Liquidity
Current Ratio
1.26x
Quick Ratio
1.13x
Debt/Equity
0.00x
Debt/Assets
40.2%
Interest Coverage
-1,929.70x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-21T04:42:10.799499 |
Data as of: 2025-09-30 |
Powered by Claude AI